HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Maureen T. Cronin, Ph.D., as the Company’s Chief Scientific Officer and Senior Vice President as of November 16, 2018. Dr. Cronin is a veteran biotechnology, translational science and diagnostic executive.
Maureen T. Cronin, Ph.D.
Chief Scientific Officer
Senior Vice President
HTG Molecular Diagnostics, Inc.
“HTG is incredibly honored to have Maureen join our company as she brings extensive experience in developing high-value precision diagnostics,” said TJ Johnson, Chief Executive Officer of HTG. “Maureen’s technology background, including most recent senior roles at Celgene, Foundation Medicine and Genomic Health, fit perfectly into HTG’s growth opportunities.”
“I met TJ several years ago and have followed the company closely since becoming aware of HTG’s technology. I believe HTG is uniquely positioned to meet the needs of next generation sequencing (NGS) based diagnostics and that the technology can be easily deployed into all labs,” said Dr. Cronin. “I’m energized to join this dynamic team and work to accelerate their pipeline of new precision diagnostic concepts and products, as well as partner with HTG’s BioPharma customers in developing best-in-class companion diagnostics.”
About Maureen T. Cronin, Ph.D.
Dr. Maureen Cronin’s brings to HTG extensive experience in genomic technology development, laboratory test development and delivery, regulatory compliance, academic clinical research and pharmaceutical company therapeutics development. Previously, Dr. Cronin was Executive Director of Strategic Information Management for Celgene Corporation, a global biopharmaceutical company engaged in the discovery, development, and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases, from 2012 to 2017. Prior to Celgene, she was Senior Vice President of Research and Product Development for Foundation Medicine, Inc., a molecular oncology diagnostics company, from 2010 to 2012. At Genomic Health, Inc., also a molecular oncology diagnostics company, Dr. Cronin was Vice President of Translation Research from 2004 to 2010 and Senior Director of Technology Development from 2001 to 2004.
Dr. Cronin is the recipient of numerous academic honors, fellowships, or awards, has over two dozen issued patents, and has written pieces for over four dozen journals and books. She received her Ph.D. at the University of California, San Diego, Department of Physiology and Pharmacology, and her M.S. and B.S. at the University of California, Davis, Department of Animal Physiology.
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed director and her expected benefits to us and the capabilities of our technology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of first party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of first parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Ashley R. Robinson
Advisors, LLC
Phone: (617) 525-7754
Email: arr@lifesciadvisors.com